TL;DR: A new study reveals that impaired cerebrovascular function—the brain’s ability to regulate blood flow—correlates strongly with Alzheimer’s symptoms, offering a potential non-invasive way to detect early cognitive decline. Alzheimer’s disease has long been framed as a problem of toxic protein accumulation: amyloid plaques and tau tangles strangling neurons into silence. But what if the …
TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin playing a critical role in triggering the brain’s own cleanup machinery. When lecanemab was approved by the FDA, it sparked hope but also raised a fundamental question: how …
TL;DR: Researchers mapped how genes are regulated differently across six brain cell types in Alzheimer’s disease, discovering that excitatory neurons drive the most extensive regulatory disruptions—and identifying key hub genes like RPS27A that could become therapeutic targets. Alzheimer’s disease is a disease of broken communication. The brain doesn’t just lose cells—it loses control, as genes …
TL;DR: Researchers discovered a toxic interaction between two brain proteins—NMDAR and TRPM4—that drives neurodegeneration in Alzheimer’s disease, and a small molecule called FP802 that blocks this “death complex” and prevents cognitive decline in mice. Alzheimer’s disease devastates the brain through multiple pathways, but the exact triggering mechanisms remain frustratingly unclear. A new study in Molecular …
TL;DR: A massive study of 27.8 million Medicare beneficiaries found that exposure to fine air pollution (PM2.5) increases Alzheimer’s risk by 8.5% per unit increase—and this effect operates largely through direct brain damage, not through common health conditions like stroke or depression. The conventional thinking about air pollution and dementia involves a detour through the …
TL;DR: Microplastics circulating in your blood may accelerate Alzheimer’s and Parkinson’s disease through six shared pathways—including blood-brain barrier breakdown, chronic inflammation, and oxidative stress. You probably know plastic pollution is everywhere. Less obvious: tiny plastic fragments are crossing into your brain, accumulating in brain tissue, and potentially triggering neurodegenerative disease. A new review in Molecular …
TL;DR: A blood test measuring phosphorylated tau-217 can predict when cognitively normal people will develop Alzheimer’s symptoms with a 3.0-3.7 year margin of error, potentially transforming how researchers identify candidates for preventive clinical trials. For decades, Alzheimer’s disease remained invisible until symptoms emerged. Brain scans could show amyloid plaques and tau tangles, but only in …
TL;DR: A new blood test using three misfolded plasma proteins can identify Alzheimer’s disease with 83.44% accuracy, outperforming conventional biomarkers and offering a non-invasive screening tool years before cognitive symptoms appear. The holy grail of Alzheimer’s research isn’t a cure—yet. It’s catching the disease before memory starts to fade. By the time someone notices confusion, …
Omega-3 supplements and Souvenaid® show potential in slowing cognitive decline in Alzheimer’s patients, though the evidence remains inconclusive. Highlights: Cognitive Decline Reduction: The CDR scale showed a significant reduction in cognitive decline progression with Omega-3 supplementation (SMD = −0.4127, 95% CI: [−0.5926; −0.2327]). Mixed Cognitive Outcomes: 58% of studies reported positive cognitive effects from Omega-3 …
ACOT7 shows promise as a non-invasive serum biomarker for Alzheimer’s disease (AD) with high diagnostic accuracy. Highlights: Increased Expression: ACOT7 levels were significantly elevated in AD patients and animal models compared to controls. Correlation with Cognitive Decline: A strong negative correlation was observed between serum ACOT7 levels and MMSE scores (r = -0.85; p < …
